Hendrix S, Dartigue V, Hall H, Bawaria S, Kingma J, Bajaj B, Zelcer N*, Kober DL*. SPRING licenses S1P-mediated cleavage of SREBP2 by displacing an inhibitory pro-domain. Nat Commun 2024;15:5732. PDF
Meurs A, Ndoj K, van den Berg M, Marinkovic G, Tantucci M, Veenendaal T, Kuivenhoven JA, Klumperman J, Zelcer N. A suite of genome-engineered hepatic cells provide novel insights into the spatiotemporal metabolism of APOB and APOB-containing lipoprotein secretion. Cardiovasc Res 2024. in press PDF
Hendrix S, Tan JME, Ndoj K, Kingma J, Valiloo M, Zijlstra LF, Ottenhoff R, Seidah NG, Loregger A, Kober DL, Zelcer N. SPRING is a Dedicated Licensing Factor for SREBP-Specific Activation by S1P. Mol Cell Biol 2024;44:123-137. PDF
D. Vacondio, H.N. Pinto, L. Coenen, I.A. Mulder, R. Fontijn, B. van het Hof, W.K. Fung, A. Jongejan, G. Kooij, N. Zelcer, A. Rozemuller, H.E. de Vries, N.M. de Wit. Liver X receptor alpha ensures blood-brain barrier function by suppressing SNAI2. Cell Death & Disease; 2023 PDF
Loix M, Zelcer N, Bogie JFJ, Hendriks JJA. The ubiquitous role of ubiquitination in lipid metabolism. Trends in Cell Biology; 2023 PDF
Hendrix S, Kingma J, Ottenhoff R, Valiloo M, Svecla M, Zijlstra LF, Sachdev V, Kovac K, Levels JHM, Jongejan A, de Boer JF, Kuipers F, Rimbert A, Norata GD, Loregger A, Zelcer N. Hepatic SREBP signaling requires SPRING to govern systemic lipid metabolism in mice and humans. Nat Commun; 2023;14:5181 PDF
Hendrix S and Zelcer N. A new SPRING in lipid metabolism. Current Opinion Lipidology; 2023 PDF
van Os BW, Vos WG, Bosmans LA, van Tiel CM, Lith SC, den Toom MS, Beckers L, Levels JHM, van Wouw SAE, Zelcer N, Zaal EA, Berkers CR, van der Lest CHA, Helms JB, Weber C, Atzler D, de Winther MPJ, Baardman J and Lutgens E. Hyperlipidaemia elicits an atypical, T helper 1-like CD4(+) T-cell response: a key role for very low-density lipoprotein. Eur Heart J Open. 2023;3:oead013. PDF
van Wouw SAE, van den Berg M, El Ouraoui M, Meurs A, Kingma J, Ottenhoff R, Loix M, Hoeksema MA, Prange K, Pasterkamp G, Hendriks JJA, Bogie JFJ, van Klinken JB, Vaz FM, Jongejan A, de Winther MPJ and Zelcer N. Sterol-regulated transmembrane protein TMEM86a couples LXR signaling to regulation of lysoplasmalogens in macrophages. J Lipid Res. 2023;64:100325. PDF
Larsen LE, van den Boogert MAW, Rios-Ocampo WA, Jansen JC, Conlon D, Chong PLE, Levels JHM, Eilers RE, Sachdev VV, Zelcer N, Raabe T, He M, Hand NJ, Drenth JPH, Rader DJ, Stroes ESG, Lefeber DJ, Jonker JW and Holleboom AG. Defective Lipid Droplet-Lysosome Interaction Causes Fatty Liver Disease as Evidenced by Human Mutations in TMEM199 and CCDC115. Cell Mol Gastroenterol Hepatol. 2022;13:583-597. PDF
Willemsen L, Prange KHM, Neele AE, van Roomen C, Gijbels M, Griffith GR, Toom MD, Beckers L, Siebeler R, Spann NJ, Chen HJ, Bosmans LA, Gorbatenko A, van Wouw S, Zelcer N, Jacobs H, van Leeuwen F and de Winther MPJ. DOT1L regulates lipid biosynthesis and inflammatory responses in macrophages and promotes atherosclerotic plaque stability. Cell Rep. 2022;41:111703. PDF
Ruffilli C, Roth S, Rodrigo M, Boyd H, Zelcer N and Moreau K. Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation. ACS Pharmacol Transl Sci. 2022;5:849-858. PDF
Kane J, Jansen M, Hendrix S, Bosmans LA, Beckers L, Tiel CV, Gijbels M, Zelcer N, Vries CJ, von Hundelshausen P, Vervloet M, Eringa E, Horrevoets AJ, Royen NV and Lutgens E. Anti-Galectin-2 Antibody Treatment Reduces Atherosclerotic Plaque Size and Alters Macrophage Polarity. Thromb Haemost. 2021. PDF
Bogie JFJ, Vanmierlo T, Vanmol J, Timmermans S, Mailleux J, Nelissen K, Wijnands E, Wouters K, Stinissen P, Gustafsson JA, Steffensen KR, Mulder M, Zelcer N and Hendriks JJA. Liver X receptor beta deficiency attenuates autoimmune-associated neuroinflammation in a T cell-dependent manner. J Autoimmun. 2021;124:102723. PDF
Clemente-Olivo MP, Habibe JJ, Vos M, Ottenhoff R, Jongejan A, Herrema H, Zelcer N, Kooijman S, Rensen PCN, Raalte DH van, Nieuwdorp M, Eringa EC, Vries CJ de. Four-and-a-half LIM domain protein 2 (FHL2) deficiency protects mice from diet-induced obesity and high FHL2 expression marks human obesity. Metabolism 2021;121:154815. PDF
van Loon NM, van Wouw SAE, Ottenhoff R, Nelson JK, Kingma J, Scheij S, Moeton M, Zelcer N. Regulation of intestinal LDLR by the LXR-IDOL axis. Atherosclerosis 2020;315:1–9. PDF
Tan JME, van der Stoel MM, van den Berg M, Van Loon NM, Moeton M, Scholl E, van der Wel NN, Kovacevic I, Hordijk PL, Loregger A, Huveneers S, Zelcer N. The MARCH6-SQLE Axis Controls Endothelial Cholesterol Homeostasis and Angiogenic Sprouting. Cell Rep2020;32:107944. PDF
Martinelli L, Adamopoulos A, Johansson P, Wan PT, Gunnarsson J, Guo H, Boyd H, Zelcer N*, Sixma TK*. Structural analysis of the LDL receptor-interacting FERM domain in the E3 ubiquitin ligase IDOL reveals an obscured substrate binding site. J Biol Chem ; 2020;:jbc.RA120.014349. PDF
Bogie JFJ, Grajchen E, Wouters E, Corrales AG, Dierckx T, Vanherle S, Mailleux J, Gervois P, Wolfs E, Dehairs J, Van Broeckhoven J, Bowman AP, Lambrichts I, Gustafsson J-A, Remaley AT, Mulder M, Swinnen JV, Haidar M, Ellis SR, Ntambi JM, Zelcer N, Hendriks JJA. Stearoyl-CoA desaturase-1 impairs the reparative properties of macrophages and microglia in the brain. J Exp Med 2020;217. PDF
Loregger A, Raaben M, Nieuwenhuis J, Tan JME, Jae LT, van den Hengel LG, Hendrix S, van den Berg M, Scheij S, Song J-Y, Huijbers IJ, Kroese LJ, Ottenhoff R, van Weeghel M, van de Sluis B, Brummelkamp T*, Zelcer N*. Haploid genetic screens identify SPRING/C12ORF49 as a determinant of SREBP signaling and cholesterol metabolism. Nat Commun; 2020;11:1128–14. PDF
van den Boogert MAW, Larsen LE, Ali L, Kuil SD, Chong PLW, Loregger A, Kroon J, Schnitzler JG, Schimmel AWM, Peter J, Levels JHM, Steenbergen G, Morava E, Dallinga-Thie GM, Wevers RA, Kuivenhoven JA, Hand NJ, Zelcer N, Rader DJ, Stroes ESG, Lefeber DJ, Holleboom AG. N-Glycosylation Defects in Humans Lower Low-Density Lipoprotein Cholesterol Through Increased Low-Density Lipoprotein Receptor Expression. Circulation 2019;140:280–292. PDF
Oteng A-B, Loregger A, van Weeghel M, Zelcer N, Kersten S. Industrial Trans Fatty Acids Stimulate SREBP2-mediated Cholesterogenesis and Promote non-alcoholic Fatty Liver Disease. Mol Nutr Food Res ; 2019;205:e1900385. PDF
van Loon NM, Lindholm D, Zelcer N. The E3 ubiquitin ligase inducible degrader of the LDL receptor/myosin light chain interacting protein in health and disease. Curr Opin Lipidol 2019;30:192–197. PDF
Pronk MCA, Majolée J, Loregger A, van Bezu JSM, Zelcer N, Hordijk PL, Kovacevic I. FBXW7 regulates endothelial barrier function by suppression of the cholesterol synthesis pathway and prenylation of RhoB. Mol Biol Cell 2019;30:607–621. PDF
Tan JME, Cook ECL, van den Berg M, Scheij S, Zelcer N*, Loregger A*. Differential use of E2 ubiquitin conjugating enzymes for regulated degradation of the rate-limiting enzymes HMGCR and SQLE in cholesterol biosynthesis. Atherosclerosis 2019;281:137–142. PDF
van Loon NM, Rensen PCN, Zelcer N. IDOL in metabolic, neurodegenerative and cardiovascular disease. Aging 2018;10:3042–3043. PDF
Koenis DS, Medzikovic L, van Loenen PB, van Weeghel M, Huveneers S, Vos M, Evers-van Gogh IJ, Van den Bossche J, Speijer D, Kim Y, Wessels L, Zelcer N, Zwart W, Kalkhoven E, de Vries CJ. Nuclear Receptor Nur77 Limits the Macrophage Inflammatory Response through Transcriptional Reprogramming of Mitochondrial Metabolism. Cell Rep 2018;24:2127–2140.e2127. PDF
van Loon NM, Ottenhoff R, Kooijman S, Moeton M, Scheij S, Roscam Abbing RLP, Gijbels MJJ, Levels JHM, Sorrentino V, Berbée JFP, Rensen PCN, Zelcer N. Inactivation of the E3 Ubiquitin Ligase IDOL (Inducible Degrader of the Low-Density Lipoprotein Receptor) Attenuates Diet-Induced Obesity and Metabolic Dysfunction in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2018;38:1785–1795. PDF
Ren L, Sun Y, Lu H, Ye D, Han L, Wang N, Daugherty A, Li F, Wang M, Su F, Tao W, Sun J, Zelcer N, Mullick AE, Danser AJ, Jiang Y, He Y, Ruan X, Lu X. (Pro)renin Receptor Inhibition Reprograms Hepatic Lipid Metabolism and Protects Mice from Diet-Induced Obesity and Hepatosteatosis. Circ Res 2018;122:730–741. PDF
Loregger A, Raaben M, Tan J, Scheij S, Moeton M, van den Berg M, Gelberg-Etel H, Stickel E, Roitelman J, Brummelkamp T, Zelcer N. Haploid Mammalian Genetic Screen Identifies UBXD8 as a Key Determinant of HMGCR Degradation and Cholesterol Biosynthesis. Arteriosclerosis, Thrombosis, and Vascular Biology; 2017;37:2064–2074. PDF
Hakonen JE, Sorrentino V, Avagliano Trezza R, de Wissel MB, van den Berg M, Bleijlevens B, van Ruissen F, Distel B, Baas F, Zelcer N*, Weterman MAJ*. LRSAM1-mediated ubiquitylation is disrupted in axonal Charcot-Marie-Tooth disease 2P. Hum Mol Genet 2017;26:2034–2041. PDF
Nelson JK, Koenis DS, Scheij S, Cook ECL, Moeton M, Santos A, Lobaccaro J-MA, Baron S, Zelcer N. EEPD1 Is a Novel LXR Target Gene in Macrophages Which Regulates ABCA1 Abundance and Cholesterol Efflux. Arteriosclerosis, Thrombosis, and Vascular Biology2017;37:423–432. PDF
Loregger A, Nelson JK, Zelcer N. Assaying Low-Density-Lipoprotein (LDL) Uptake into Cells. In: Gelissen IC, Brown AJ, eds. Cholesterol Homeostasis New York, NY: Springer New York; 2017. p. 53–63. PDF
Cook ECL, Nelson JK, Sorrentino V, Koenis D, Moeton M, Scheij S, Ottenhoff R, Bleijlevens B, Loregger A, Zelcer N. Identification of the ER-resident E3 ubiquitin ligase RNF145 as a novel LXR-regulated gene. PLoS ONE 2017;12:e0172721. PDF
Van Loon NM, Zelcer N. Idolizing the clearance of Amyloid-β by microglia. Ann Transl Med2016;4:536–536. PDF
Tol MJ, Ottenhoff R, van Eijk M, Zelcer N, Aten J, Houten SM, Geerts D, van Roomen C, Bierlaagh MC, Scheij S, Hoeksema MA, Aerts JM, Bogan JS, Dorn GW, Argmann CA, Verhoeven AJ. A PPARγ-Bnip3 Axis Couples Adipose Mitochondrial Fusion-Fission Balance to Systemic Insulin Sensitivity. Diabetes 2016;65:2591–2605. PDF
Nelson JK, Cook ECL, Loregger A, Hoeksema MA, Scheij S, Kovacevic I, Hordijk PL, Ovaa H, Zelcer N. Deubiquitylase Inhibition Reveals Liver X Receptor-independent Transcriptional Regulation of the E3 Ubiquitin Ligase IDOL and Lipoprotein Uptake. J Biol Chem 2016;291:4813–4825. PDF
Nelson JK, Sorrentino V, Avagliano Trezza R, Heride C, Urbé S, Distel B, Zelcer N. The Deubiquitylase USP2 Regulates the LDLR Pathway by Counteracting the E3-Ubiquitin Ligase IDOL. Circ Res 2016;118:410–419. PDF
Lu X, Meima ME, Nelson JK, Sorrentino V, Loregger A, Scheij S, Dekkers DHW, Mulder MT, Demmers JAA, M-Dallinga-Thie G, Zelcer N*, Danser AHJ*. Identification of the (Pro)renin Receptor as a Novel Regulator of Low-Density Lipoprotein Metabolism. Circ Res 2016;118:222–229. PDF
Loregger A, Cook ECL, Nelson JK, Moeton M, Sharpe LJ, Engberg S, Karimova M, Lambert G, Brown AJ, Zelcer N. A MARCH6 and IDOL E3 Ubiquitin Ligase Circuit Uncouples Cholesterol Synthesis from Lipoprotein Uptake in Hepatocytes. Mol Cell Biol ; 2016;36:285–294. PDF
De Boussac H, Maqdasy S, Trousson A, Zelcer N, Volle DH, Lobaccaro J-MA, Baron S. Enolase is regulated by Liver X Receptors. Steroids 2015;99:266–271. PDF
Kurakula K, Sommer D, Sokolovic M, Moerland PD, Scheij S, van Loenen PB, Koenis DS, Zelcer N, van Tiel CM, de Vries CJM. LIM-only protein FHL2 is a positive regulator of liver X receptors in smooth muscle cells involved in lipid homeostasis. Mol Cell Biol 2015;35:52–62. PDF
Kizhakkedath P, Loregger A, John A, Bleijlevens B, Al-Blooshi AS, Al-Hosani AH, Al-Nuaimi AM, Al-Gazali L, Zelcer N, Ali BR. Impaired trafficking of the very low density lipoprotein receptor caused by missense mutations associated with dysequilibrium syndrome. Biochim Biophys Acta2014;1843:2871–2877. PDF
Sharpe LJ, Cook ECL, Zelcer N*, Brown AJ*. The UPS and downs of cholesterol homeostasis. Trends Biochem Sci 2014;39:527–535. PDF
Fouchier SW, Dallinga-Thie GM, Meijers JCM, Zelcer N, Kastelein JJP, Defesche JC, Hovingh GK. Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia. Circ Res; 2014;115:552–555. PDF
Zelcer N, Westerterp M. Adeno-associated viruses as a method to induce atherosclerosis in mice and hamsters. Circ Res 2014;114:1672–1674. PDF
Zelcer N*, Sharpe LJ, Loregger A, Kristiana I, Cook ECL, Phan L, Stevenson J, Brown AJ*. The E3 ubiquitin ligase MARCH6 degrades squalene monooxygenase and affects 3-hydroxy-3-methyl-glutaryl coenzyme A reductase and the cholesterol synthesis pathway. Mol Cell Biol2014;34:1262–1270. PDF
Sharpe LJ, Cook ECL, Zelcer N*, Brown AJ*. The UPS and downs of cholesterol homeostasis. Trends Biochem Sci ; 2014;39:527–535. PDF
Pietiäinen V, Vassilev B, Blom T, Wang W, Nelson J, Bittman R, Bäck N, Zelcer N, Ikonen E. NDRG1 functions in LDL receptor trafficking by regulating endosomal recycling and degradation. J Cell Sci 2013;126:3961–3971. PDF
Sorrentino V, Nelson JK, Maspero E, Marques ARA, Scheer L, Polo S, Zelcer N. The LXR-IDOL axis defines a clathrin-, caveolae-, and dynamin-independent endocytic route for LDLR internalization and lysosomal degradation. J Lipid Res 2013;54:2174–2184. PDF
Sorrentino V, Fouchier SW, Motazacker MM, Nelson JK, Defesche JC, Dallinga-Thie GM, Kastelein JJP, Kees Hovingh G, Zelcer N. Identification of a loss-of-function inducible degrader of the low-density lipoprotein receptor variant in individuals with low circulating low-density lipoprotein. Eur Heart J 2013;34:1292–1297. PDF
Bogie JFJ, Jorissen W, Mailleux J, Nijland PG, Zelcer N, Vanmierlo T, Van Horssen J, Stinissen P, Hellings N, Hendriks JJA. Myelin alters the inflammatory phenotype of macrophages by activating PPARs. Acta Neuropathol Commun 2013;1:43. PDF
Motazacker MM, Pirruccello J, Huijgen R, Do R, Gabriel S, Peter J, Kuivenhoven JA, Defesche JC, Kastelein JJP, Hovingh GK, Zelcer N, Kathiresan S, Fouchier SW. Advances in genetics show the need for extending screening strategies for autosomal dominant hypercholesterolaemia. Eur Heart J; 2012;33:1360–1366. PDF
Sorrentino V, Zelcer N. Post-transcriptional regulation of lipoprotein receptors by the E3-ubiquitin ligase inducible degrader of the low-density lipoprotein receptor. Curr Opin Lipidol 2012;23:213–219. PDF
Do HT, Tselykh TV, Mäkelä J, Ho TH, Olkkonen VM, Bornhauser BC, Korhonen L, Zelcer N, Lindholm D. Fibroblast growth factor-21 (FGF21) regulates low-density lipoprotein receptor (LDLR) levels in cells via the E3-ubiquitin ligase Mylip/Idol and the Canopy2 (Cnpy2)/Mylip-interacting saposin-like protein (Msap). J Biol Chem 2012;287:12602–12611. PDF
Weterman MAJ, Sorrentino V, Kasher PR, Jakobs ME, van Engelen BGM, Fluiter K, de Wissel MB, Sizarov A, Nürnberg G, Nürnberg P, Zelcer N, Schelhaas HJ, Baas F. A frameshift mutation in LRSAM1 is responsible for a dominant hereditary polyneuropathy. Hum Mol Genet 2012;21:358–370. PDF
Sorrentino V, Scheer L, Santos A, Reits E, Bleijlevens B, Zelcer N. Distinct functional domains contribute to degradation of the low density lipoprotein receptor (LDLR) by the E3 ubiquitin ligase inducible Degrader of the LDLR (IDOL). J Biol Chem 2011;286:30190–30199. PDF
Weissglas-Volkov D, Calkin AC, Tusie-Luna T, Sinsheimer JS, Zelcer N, Riba L, Tino AMV, Ordoñez-Sánchez ML, Cruz-Bautista I, Aguilar-Salinas CA, Tontonoz P, Pajukanta P. The N342S MYLIP polymorphism is associated with high total cholesterol and increased LDL receptor degradation in humans. 2011;121:3062–3071. PDF
Scotti E, Hong C, Yoshinaga Y, Tu Y, Hu Y, Zelcer N, Boyadjian R, de Jong PJ, Young SG, Fong LG, Tontonoz P. Targeted disruption of the idol gene alters cellular regulation of the low-density lipoprotein receptor by sterols and liver x receptor agonists. Mol Cell Biol 2011;31:1885–1893. PDF
Hong C, Duit S, Jalonen P, Out R, Scheer L, Sorrentino V, Boyadjian R, Rodenburg KW, Foley E, Korhonen L, Lindholm D, Nimpf J, van Berkel TJC, Tontonoz P, Zelcer N. The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2. J Biol Chem 2010;285:19720–19726. PDF
A-Gonzalez N, Bensinger SJ, Hong C, Beceiro S, Bradley MN, Zelcer N, Deniz J, Ramirez C, Díaz M, Gallardo G, de Galarreta CR, Salazar J, Lopez F, Edwards P, Parks J, Andujar M, Tontonoz P, Castrillo A. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 2009;31:245–258. PDF
Zelcer N, Hong C, Boyadjian R, Tontonoz P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 2009;325:100–104. PDF
Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, Hausner MA, Shih R, Parks JS, Edwards PA, Jamieson BD, Tontonoz P. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 2008;134:97–111. PDF
Jiang Q, Lee CYD, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE. ApoE promotes the proteolytic degradation of Abeta. Neuron 2008;58:681–693. PDF
van de Wetering K, Zelcer N, Kuil A, Feddema W, Hillebrand M, Vlaming MLH, Schinkel AH, Beijnen JH, Borst P. Multidrug resistance proteins 2 and 3 provide alternative routes for hepatic excretion of morphine-glucuronides. Mol Pharmacol 2007;72:387–394. PDF
Zelcer N, Khanlou N, Clare R, Jiang Q, Reed-Geaghan EG, Landreth GE, Vinters HV, Tontonoz P. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc Natl Acad Sci USA 2007;104:10601–10606. PDF
Zelcer N, van de Wetering K, de Waart R, Scheffer GL, Marschall H-U, Wielinga PR, Kuil A, Kunne C, Smith A, van der Valk M, Wijnholds J, Elferink RO, Borst P. Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. J Hepatol 2006;44:768–775. PDF
Borst P, Zelcer N, van de Wetering K. MRP2 and 3 in health and disease. Cancer Lett2006;234:51–61. PDF
Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 2006;116:607–614. PDF
Borst P, Zelcer N, van de Wetering K, Poolman B. On the putative co-transport of drugs by multidrug resistance proteins. 2006;580:1085–1093. PDF
Manautou JE, de Waart DR, Kunne C, Zelcer N, Goedken M, Borst P, Elferink RO. Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene. Hepatology2005;42:1091–1098. PDF
Zelcer N, Tontonoz P. SUMOylation and PPARgamma: wrestling with inflammatory signaling. 2005;2:273–275. PDF
Pichler A, Zelcer N, Prior JL, Kuil AJ, Piwnica-Worms D. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin Cancer Res 2005;11:4487–4494. PDF
Zelcer N, van de Wetering K, Hillebrand M, Sarton E, Kuil A, Wielinga PR, Tephly T, Dahan A, Beijnen JH, Borst P. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc Natl Acad Sci USA2005;102:7274–7279. PDF
Wielinga P, Hooijberg JH, Gunnarsdottir S, Kathmann I, Reid G, Zelcer N, van der Born K, de Haas M, van der Heijden I, Kaspers G, Wijnholds J, Jansen G, Peters G, Borst P. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res 2005;65:4425–4430. PDF
Breedveld P, Zelcer N, Pluim D, Sönmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, Schellens JHM. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 2004;64:5804–5811. PDF
Assem M, Schuetz EG, Leggas M, Sun D, Yasuda K, Reid G, Zelcer N, Adachi M, Strom S, Evans RM, Moore DD, Borst P, Schuetz JD. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem2004;279:22250–22257. PDF
Borst P, Balzarini J, Ono N, Reid G, de Vries H, Wielinga P, Wijnholds J, Zelcer N. The potential impact of drug transporters on nucleoside-analog-based antiviral chemotherapy. Antiviral Res2004;62:1–7. PDF
Cummings J, Zelcer N, Allen JD, Yao D, Boyd G, Maliepaard M, Friedberg TH, Smyth JF, Jodrell DI. Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins. Biochem Pharmacol 2004;67:31–39. PDF
Reid G*, Wielinga P*, Zelcer N*, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci USA 2003;100:9244–9249. PDF
Zelcer N, Huisman MT, Reid G, Wielinga P, Breedveld P, Kuil A, Knipscheer P, Schellens JHM, Schinkel AH, Borst P. Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem 2003;278:23538–23544. PDF
Reid G, Wielinga P, Zelcer N, de Haas M, Van Deemter L, Wijnholds J, Balzarini J, Borst P. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol 2003;63:1094–1103. PDF
Zelcer N*, Reid G*, Wielinga P, Kuil A, van der Heijden I, Schuetz JD, Borst P. Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J 2003;371:361–367. PDF
Zelcer N, Saeki T, Bot I, Kuil A, Borst P. Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter. Biochem J2003;369:23–30. PDF
Huisman MT, Smit JW, Crommentuyn KML, Zelcer N, Wiltshire HR, Beijnen JH, Schinkel AH. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 2002;16:2295–2301. PDF
Burg D, Wielinga P, Zelcer N, Saeki T, Mulder GJ, Borst P. Inhibition of the multidrug resistance protein 1 (MRP1) by peptidomimetic glutathione-conjugate analogs. Mol Pharmacol2002;62:1160–1166. PDF
Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P. Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem 2001;276:46400–46407. PDF
Borst P, Zelcer N, van Helvoort A. ABC transporters in lipid transport. Biochim Biophys Acta2000;1486:128–144. PDF
Meurs A, Ndoj K, van den Berg M, Marinkovic G, Tantucci M, Veenendaal T, Kuivenhoven JA, Klumperman J, Zelcer N. A suite of genome-engineered hepatic cells provide novel insights into the spatiotemporal metabolism of APOB and APOB-containing lipoprotein secretion. Cardiovasc Res 2024. in press PDF
Hendrix S, Tan JME, Ndoj K, Kingma J, Valiloo M, Zijlstra LF, Ottenhoff R, Seidah NG, Loregger A, Kober DL, Zelcer N. SPRING is a Dedicated Licensing Factor for SREBP-Specific Activation by S1P. Mol Cell Biol 2024;44:123-137. PDF
D. Vacondio, H.N. Pinto, L. Coenen, I.A. Mulder, R. Fontijn, B. van het Hof, W.K. Fung, A. Jongejan, G. Kooij, N. Zelcer, A. Rozemuller, H.E. de Vries, N.M. de Wit. Liver X receptor alpha ensures blood-brain barrier function by suppressing SNAI2. Cell Death & Disease; 2023 PDF
Loix M, Zelcer N, Bogie JFJ, Hendriks JJA. The ubiquitous role of ubiquitination in lipid metabolism. Trends in Cell Biology; 2023 PDF
Hendrix S, Kingma J, Ottenhoff R, Valiloo M, Svecla M, Zijlstra LF, Sachdev V, Kovac K, Levels JHM, Jongejan A, de Boer JF, Kuipers F, Rimbert A, Norata GD, Loregger A, Zelcer N. Hepatic SREBP signaling requires SPRING to govern systemic lipid metabolism in mice and humans. Nat Commun; 2023;14:5181 PDF
Hendrix S and Zelcer N. A new SPRING in lipid metabolism. Current Opinion Lipidology; 2023 PDF
van Os BW, Vos WG, Bosmans LA, van Tiel CM, Lith SC, den Toom MS, Beckers L, Levels JHM, van Wouw SAE, Zelcer N, Zaal EA, Berkers CR, van der Lest CHA, Helms JB, Weber C, Atzler D, de Winther MPJ, Baardman J and Lutgens E. Hyperlipidaemia elicits an atypical, T helper 1-like CD4(+) T-cell response: a key role for very low-density lipoprotein. Eur Heart J Open. 2023;3:oead013. PDF
van Wouw SAE, van den Berg M, El Ouraoui M, Meurs A, Kingma J, Ottenhoff R, Loix M, Hoeksema MA, Prange K, Pasterkamp G, Hendriks JJA, Bogie JFJ, van Klinken JB, Vaz FM, Jongejan A, de Winther MPJ and Zelcer N. Sterol-regulated transmembrane protein TMEM86a couples LXR signaling to regulation of lysoplasmalogens in macrophages. J Lipid Res. 2023;64:100325. PDF
Larsen LE, van den Boogert MAW, Rios-Ocampo WA, Jansen JC, Conlon D, Chong PLE, Levels JHM, Eilers RE, Sachdev VV, Zelcer N, Raabe T, He M, Hand NJ, Drenth JPH, Rader DJ, Stroes ESG, Lefeber DJ, Jonker JW and Holleboom AG. Defective Lipid Droplet-Lysosome Interaction Causes Fatty Liver Disease as Evidenced by Human Mutations in TMEM199 and CCDC115. Cell Mol Gastroenterol Hepatol. 2022;13:583-597. PDF
Willemsen L, Prange KHM, Neele AE, van Roomen C, Gijbels M, Griffith GR, Toom MD, Beckers L, Siebeler R, Spann NJ, Chen HJ, Bosmans LA, Gorbatenko A, van Wouw S, Zelcer N, Jacobs H, van Leeuwen F and de Winther MPJ. DOT1L regulates lipid biosynthesis and inflammatory responses in macrophages and promotes atherosclerotic plaque stability. Cell Rep. 2022;41:111703. PDF
Ruffilli C, Roth S, Rodrigo M, Boyd H, Zelcer N and Moreau K. Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation. ACS Pharmacol Transl Sci. 2022;5:849-858. PDF
Kane J, Jansen M, Hendrix S, Bosmans LA, Beckers L, Tiel CV, Gijbels M, Zelcer N, Vries CJ, von Hundelshausen P, Vervloet M, Eringa E, Horrevoets AJ, Royen NV and Lutgens E. Anti-Galectin-2 Antibody Treatment Reduces Atherosclerotic Plaque Size and Alters Macrophage Polarity. Thromb Haemost. 2021. PDF
Bogie JFJ, Vanmierlo T, Vanmol J, Timmermans S, Mailleux J, Nelissen K, Wijnands E, Wouters K, Stinissen P, Gustafsson JA, Steffensen KR, Mulder M, Zelcer N and Hendriks JJA. Liver X receptor beta deficiency attenuates autoimmune-associated neuroinflammation in a T cell-dependent manner. J Autoimmun. 2021;124:102723. PDF
Clemente-Olivo MP, Habibe JJ, Vos M, Ottenhoff R, Jongejan A, Herrema H, Zelcer N, Kooijman S, Rensen PCN, Raalte DH van, Nieuwdorp M, Eringa EC, Vries CJ de. Four-and-a-half LIM domain protein 2 (FHL2) deficiency protects mice from diet-induced obesity and high FHL2 expression marks human obesity. Metabolism 2021;121:154815. PDF
van Loon NM, van Wouw SAE, Ottenhoff R, Nelson JK, Kingma J, Scheij S, Moeton M, Zelcer N. Regulation of intestinal LDLR by the LXR-IDOL axis. Atherosclerosis 2020;315:1–9. PDF
Tan JME, van der Stoel MM, van den Berg M, Van Loon NM, Moeton M, Scholl E, van der Wel NN, Kovacevic I, Hordijk PL, Loregger A, Huveneers S, Zelcer N. The MARCH6-SQLE Axis Controls Endothelial Cholesterol Homeostasis and Angiogenic Sprouting. Cell Rep2020;32:107944. PDF
Martinelli L, Adamopoulos A, Johansson P, Wan PT, Gunnarsson J, Guo H, Boyd H, Zelcer N*, Sixma TK*. Structural analysis of the LDL receptor-interacting FERM domain in the E3 ubiquitin ligase IDOL reveals an obscured substrate binding site. J Biol Chem ; 2020;:jbc.RA120.014349. PDF
Bogie JFJ, Grajchen E, Wouters E, Corrales AG, Dierckx T, Vanherle S, Mailleux J, Gervois P, Wolfs E, Dehairs J, Van Broeckhoven J, Bowman AP, Lambrichts I, Gustafsson J-A, Remaley AT, Mulder M, Swinnen JV, Haidar M, Ellis SR, Ntambi JM, Zelcer N, Hendriks JJA. Stearoyl-CoA desaturase-1 impairs the reparative properties of macrophages and microglia in the brain. J Exp Med 2020;217. PDF
Loregger A, Raaben M, Nieuwenhuis J, Tan JME, Jae LT, van den Hengel LG, Hendrix S, van den Berg M, Scheij S, Song J-Y, Huijbers IJ, Kroese LJ, Ottenhoff R, van Weeghel M, van de Sluis B, Brummelkamp T*, Zelcer N*. Haploid genetic screens identify SPRING/C12ORF49 as a determinant of SREBP signaling and cholesterol metabolism. Nat Commun; 2020;11:1128–14. PDF
van den Boogert MAW, Larsen LE, Ali L, Kuil SD, Chong PLW, Loregger A, Kroon J, Schnitzler JG, Schimmel AWM, Peter J, Levels JHM, Steenbergen G, Morava E, Dallinga-Thie GM, Wevers RA, Kuivenhoven JA, Hand NJ, Zelcer N, Rader DJ, Stroes ESG, Lefeber DJ, Holleboom AG. N-Glycosylation Defects in Humans Lower Low-Density Lipoprotein Cholesterol Through Increased Low-Density Lipoprotein Receptor Expression. Circulation 2019;140:280–292. PDF
Oteng A-B, Loregger A, van Weeghel M, Zelcer N, Kersten S. Industrial Trans Fatty Acids Stimulate SREBP2-mediated Cholesterogenesis and Promote non-alcoholic Fatty Liver Disease. Mol Nutr Food Res ; 2019;205:e1900385. PDF
van Loon NM, Lindholm D, Zelcer N. The E3 ubiquitin ligase inducible degrader of the LDL receptor/myosin light chain interacting protein in health and disease. Curr Opin Lipidol 2019;30:192–197. PDF
Pronk MCA, Majolée J, Loregger A, van Bezu JSM, Zelcer N, Hordijk PL, Kovacevic I. FBXW7 regulates endothelial barrier function by suppression of the cholesterol synthesis pathway and prenylation of RhoB. Mol Biol Cell 2019;30:607–621. PDF
Tan JME, Cook ECL, van den Berg M, Scheij S, Zelcer N*, Loregger A*. Differential use of E2 ubiquitin conjugating enzymes for regulated degradation of the rate-limiting enzymes HMGCR and SQLE in cholesterol biosynthesis. Atherosclerosis 2019;281:137–142. PDF
van Loon NM, Rensen PCN, Zelcer N. IDOL in metabolic, neurodegenerative and cardiovascular disease. Aging 2018;10:3042–3043. PDF
Koenis DS, Medzikovic L, van Loenen PB, van Weeghel M, Huveneers S, Vos M, Evers-van Gogh IJ, Van den Bossche J, Speijer D, Kim Y, Wessels L, Zelcer N, Zwart W, Kalkhoven E, de Vries CJ. Nuclear Receptor Nur77 Limits the Macrophage Inflammatory Response through Transcriptional Reprogramming of Mitochondrial Metabolism. Cell Rep 2018;24:2127–2140.e2127. PDF
van Loon NM, Ottenhoff R, Kooijman S, Moeton M, Scheij S, Roscam Abbing RLP, Gijbels MJJ, Levels JHM, Sorrentino V, Berbée JFP, Rensen PCN, Zelcer N. Inactivation of the E3 Ubiquitin Ligase IDOL (Inducible Degrader of the Low-Density Lipoprotein Receptor) Attenuates Diet-Induced Obesity and Metabolic Dysfunction in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2018;38:1785–1795. PDF
Ren L, Sun Y, Lu H, Ye D, Han L, Wang N, Daugherty A, Li F, Wang M, Su F, Tao W, Sun J, Zelcer N, Mullick AE, Danser AJ, Jiang Y, He Y, Ruan X, Lu X. (Pro)renin Receptor Inhibition Reprograms Hepatic Lipid Metabolism and Protects Mice from Diet-Induced Obesity and Hepatosteatosis. Circ Res 2018;122:730–741. PDF
Loregger A, Raaben M, Tan J, Scheij S, Moeton M, van den Berg M, Gelberg-Etel H, Stickel E, Roitelman J, Brummelkamp T, Zelcer N. Haploid Mammalian Genetic Screen Identifies UBXD8 as a Key Determinant of HMGCR Degradation and Cholesterol Biosynthesis. Arteriosclerosis, Thrombosis, and Vascular Biology; 2017;37:2064–2074. PDF
Hakonen JE, Sorrentino V, Avagliano Trezza R, de Wissel MB, van den Berg M, Bleijlevens B, van Ruissen F, Distel B, Baas F, Zelcer N*, Weterman MAJ*. LRSAM1-mediated ubiquitylation is disrupted in axonal Charcot-Marie-Tooth disease 2P. Hum Mol Genet 2017;26:2034–2041. PDF
Nelson JK, Koenis DS, Scheij S, Cook ECL, Moeton M, Santos A, Lobaccaro J-MA, Baron S, Zelcer N. EEPD1 Is a Novel LXR Target Gene in Macrophages Which Regulates ABCA1 Abundance and Cholesterol Efflux. Arteriosclerosis, Thrombosis, and Vascular Biology2017;37:423–432. PDF
Loregger A, Nelson JK, Zelcer N. Assaying Low-Density-Lipoprotein (LDL) Uptake into Cells. In: Gelissen IC, Brown AJ, eds. Cholesterol Homeostasis New York, NY: Springer New York; 2017. p. 53–63. PDF
Cook ECL, Nelson JK, Sorrentino V, Koenis D, Moeton M, Scheij S, Ottenhoff R, Bleijlevens B, Loregger A, Zelcer N. Identification of the ER-resident E3 ubiquitin ligase RNF145 as a novel LXR-regulated gene. PLoS ONE 2017;12:e0172721. PDF
Van Loon NM, Zelcer N. Idolizing the clearance of Amyloid-β by microglia. Ann Transl Med2016;4:536–536. PDF
Tol MJ, Ottenhoff R, van Eijk M, Zelcer N, Aten J, Houten SM, Geerts D, van Roomen C, Bierlaagh MC, Scheij S, Hoeksema MA, Aerts JM, Bogan JS, Dorn GW, Argmann CA, Verhoeven AJ. A PPARγ-Bnip3 Axis Couples Adipose Mitochondrial Fusion-Fission Balance to Systemic Insulin Sensitivity. Diabetes 2016;65:2591–2605. PDF
Nelson JK, Cook ECL, Loregger A, Hoeksema MA, Scheij S, Kovacevic I, Hordijk PL, Ovaa H, Zelcer N. Deubiquitylase Inhibition Reveals Liver X Receptor-independent Transcriptional Regulation of the E3 Ubiquitin Ligase IDOL and Lipoprotein Uptake. J Biol Chem 2016;291:4813–4825. PDF
Nelson JK, Sorrentino V, Avagliano Trezza R, Heride C, Urbé S, Distel B, Zelcer N. The Deubiquitylase USP2 Regulates the LDLR Pathway by Counteracting the E3-Ubiquitin Ligase IDOL. Circ Res 2016;118:410–419. PDF
Lu X, Meima ME, Nelson JK, Sorrentino V, Loregger A, Scheij S, Dekkers DHW, Mulder MT, Demmers JAA, M-Dallinga-Thie G, Zelcer N*, Danser AHJ*. Identification of the (Pro)renin Receptor as a Novel Regulator of Low-Density Lipoprotein Metabolism. Circ Res 2016;118:222–229. PDF
Loregger A, Cook ECL, Nelson JK, Moeton M, Sharpe LJ, Engberg S, Karimova M, Lambert G, Brown AJ, Zelcer N. A MARCH6 and IDOL E3 Ubiquitin Ligase Circuit Uncouples Cholesterol Synthesis from Lipoprotein Uptake in Hepatocytes. Mol Cell Biol ; 2016;36:285–294. PDF
De Boussac H, Maqdasy S, Trousson A, Zelcer N, Volle DH, Lobaccaro J-MA, Baron S. Enolase is regulated by Liver X Receptors. Steroids 2015;99:266–271. PDF
Kurakula K, Sommer D, Sokolovic M, Moerland PD, Scheij S, van Loenen PB, Koenis DS, Zelcer N, van Tiel CM, de Vries CJM. LIM-only protein FHL2 is a positive regulator of liver X receptors in smooth muscle cells involved in lipid homeostasis. Mol Cell Biol 2015;35:52–62. PDF
Kizhakkedath P, Loregger A, John A, Bleijlevens B, Al-Blooshi AS, Al-Hosani AH, Al-Nuaimi AM, Al-Gazali L, Zelcer N, Ali BR. Impaired trafficking of the very low density lipoprotein receptor caused by missense mutations associated with dysequilibrium syndrome. Biochim Biophys Acta2014;1843:2871–2877. PDF
Sharpe LJ, Cook ECL, Zelcer N*, Brown AJ*. The UPS and downs of cholesterol homeostasis. Trends Biochem Sci 2014;39:527–535. PDF
Fouchier SW, Dallinga-Thie GM, Meijers JCM, Zelcer N, Kastelein JJP, Defesche JC, Hovingh GK. Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia. Circ Res; 2014;115:552–555. PDF
Zelcer N, Westerterp M. Adeno-associated viruses as a method to induce atherosclerosis in mice and hamsters. Circ Res 2014;114:1672–1674. PDF
Zelcer N*, Sharpe LJ, Loregger A, Kristiana I, Cook ECL, Phan L, Stevenson J, Brown AJ*. The E3 ubiquitin ligase MARCH6 degrades squalene monooxygenase and affects 3-hydroxy-3-methyl-glutaryl coenzyme A reductase and the cholesterol synthesis pathway. Mol Cell Biol2014;34:1262–1270. PDF
Sharpe LJ, Cook ECL, Zelcer N*, Brown AJ*. The UPS and downs of cholesterol homeostasis. Trends Biochem Sci ; 2014;39:527–535. PDF
Pietiäinen V, Vassilev B, Blom T, Wang W, Nelson J, Bittman R, Bäck N, Zelcer N, Ikonen E. NDRG1 functions in LDL receptor trafficking by regulating endosomal recycling and degradation. J Cell Sci 2013;126:3961–3971. PDF
Sorrentino V, Nelson JK, Maspero E, Marques ARA, Scheer L, Polo S, Zelcer N. The LXR-IDOL axis defines a clathrin-, caveolae-, and dynamin-independent endocytic route for LDLR internalization and lysosomal degradation. J Lipid Res 2013;54:2174–2184. PDF
Sorrentino V, Fouchier SW, Motazacker MM, Nelson JK, Defesche JC, Dallinga-Thie GM, Kastelein JJP, Kees Hovingh G, Zelcer N. Identification of a loss-of-function inducible degrader of the low-density lipoprotein receptor variant in individuals with low circulating low-density lipoprotein. Eur Heart J 2013;34:1292–1297. PDF
Bogie JFJ, Jorissen W, Mailleux J, Nijland PG, Zelcer N, Vanmierlo T, Van Horssen J, Stinissen P, Hellings N, Hendriks JJA. Myelin alters the inflammatory phenotype of macrophages by activating PPARs. Acta Neuropathol Commun 2013;1:43. PDF
Motazacker MM, Pirruccello J, Huijgen R, Do R, Gabriel S, Peter J, Kuivenhoven JA, Defesche JC, Kastelein JJP, Hovingh GK, Zelcer N, Kathiresan S, Fouchier SW. Advances in genetics show the need for extending screening strategies for autosomal dominant hypercholesterolaemia. Eur Heart J; 2012;33:1360–1366. PDF
Sorrentino V, Zelcer N. Post-transcriptional regulation of lipoprotein receptors by the E3-ubiquitin ligase inducible degrader of the low-density lipoprotein receptor. Curr Opin Lipidol 2012;23:213–219. PDF
Do HT, Tselykh TV, Mäkelä J, Ho TH, Olkkonen VM, Bornhauser BC, Korhonen L, Zelcer N, Lindholm D. Fibroblast growth factor-21 (FGF21) regulates low-density lipoprotein receptor (LDLR) levels in cells via the E3-ubiquitin ligase Mylip/Idol and the Canopy2 (Cnpy2)/Mylip-interacting saposin-like protein (Msap). J Biol Chem 2012;287:12602–12611. PDF
Weterman MAJ, Sorrentino V, Kasher PR, Jakobs ME, van Engelen BGM, Fluiter K, de Wissel MB, Sizarov A, Nürnberg G, Nürnberg P, Zelcer N, Schelhaas HJ, Baas F. A frameshift mutation in LRSAM1 is responsible for a dominant hereditary polyneuropathy. Hum Mol Genet 2012;21:358–370. PDF
Sorrentino V, Scheer L, Santos A, Reits E, Bleijlevens B, Zelcer N. Distinct functional domains contribute to degradation of the low density lipoprotein receptor (LDLR) by the E3 ubiquitin ligase inducible Degrader of the LDLR (IDOL). J Biol Chem 2011;286:30190–30199. PDF
Weissglas-Volkov D, Calkin AC, Tusie-Luna T, Sinsheimer JS, Zelcer N, Riba L, Tino AMV, Ordoñez-Sánchez ML, Cruz-Bautista I, Aguilar-Salinas CA, Tontonoz P, Pajukanta P. The N342S MYLIP polymorphism is associated with high total cholesterol and increased LDL receptor degradation in humans. 2011;121:3062–3071. PDF
Scotti E, Hong C, Yoshinaga Y, Tu Y, Hu Y, Zelcer N, Boyadjian R, de Jong PJ, Young SG, Fong LG, Tontonoz P. Targeted disruption of the idol gene alters cellular regulation of the low-density lipoprotein receptor by sterols and liver x receptor agonists. Mol Cell Biol 2011;31:1885–1893. PDF
Hong C, Duit S, Jalonen P, Out R, Scheer L, Sorrentino V, Boyadjian R, Rodenburg KW, Foley E, Korhonen L, Lindholm D, Nimpf J, van Berkel TJC, Tontonoz P, Zelcer N. The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2. J Biol Chem 2010;285:19720–19726. PDF
A-Gonzalez N, Bensinger SJ, Hong C, Beceiro S, Bradley MN, Zelcer N, Deniz J, Ramirez C, Díaz M, Gallardo G, de Galarreta CR, Salazar J, Lopez F, Edwards P, Parks J, Andujar M, Tontonoz P, Castrillo A. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 2009;31:245–258. PDF
Zelcer N, Hong C, Boyadjian R, Tontonoz P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 2009;325:100–104. PDF
Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, Hausner MA, Shih R, Parks JS, Edwards PA, Jamieson BD, Tontonoz P. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 2008;134:97–111. PDF
Jiang Q, Lee CYD, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE. ApoE promotes the proteolytic degradation of Abeta. Neuron 2008;58:681–693. PDF
van de Wetering K, Zelcer N, Kuil A, Feddema W, Hillebrand M, Vlaming MLH, Schinkel AH, Beijnen JH, Borst P. Multidrug resistance proteins 2 and 3 provide alternative routes for hepatic excretion of morphine-glucuronides. Mol Pharmacol 2007;72:387–394. PDF
Zelcer N, Khanlou N, Clare R, Jiang Q, Reed-Geaghan EG, Landreth GE, Vinters HV, Tontonoz P. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc Natl Acad Sci USA 2007;104:10601–10606. PDF
Zelcer N, van de Wetering K, de Waart R, Scheffer GL, Marschall H-U, Wielinga PR, Kuil A, Kunne C, Smith A, van der Valk M, Wijnholds J, Elferink RO, Borst P. Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. J Hepatol 2006;44:768–775. PDF
Borst P, Zelcer N, van de Wetering K. MRP2 and 3 in health and disease. Cancer Lett2006;234:51–61. PDF
Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 2006;116:607–614. PDF
Borst P, Zelcer N, van de Wetering K, Poolman B. On the putative co-transport of drugs by multidrug resistance proteins. 2006;580:1085–1093. PDF
Manautou JE, de Waart DR, Kunne C, Zelcer N, Goedken M, Borst P, Elferink RO. Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene. Hepatology2005;42:1091–1098. PDF
Zelcer N, Tontonoz P. SUMOylation and PPARgamma: wrestling with inflammatory signaling. 2005;2:273–275. PDF
Pichler A, Zelcer N, Prior JL, Kuil AJ, Piwnica-Worms D. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin Cancer Res 2005;11:4487–4494. PDF
Zelcer N, van de Wetering K, Hillebrand M, Sarton E, Kuil A, Wielinga PR, Tephly T, Dahan A, Beijnen JH, Borst P. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc Natl Acad Sci USA2005;102:7274–7279. PDF
Wielinga P, Hooijberg JH, Gunnarsdottir S, Kathmann I, Reid G, Zelcer N, van der Born K, de Haas M, van der Heijden I, Kaspers G, Wijnholds J, Jansen G, Peters G, Borst P. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res 2005;65:4425–4430. PDF
Breedveld P, Zelcer N, Pluim D, Sönmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, Schellens JHM. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 2004;64:5804–5811. PDF
Assem M, Schuetz EG, Leggas M, Sun D, Yasuda K, Reid G, Zelcer N, Adachi M, Strom S, Evans RM, Moore DD, Borst P, Schuetz JD. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem2004;279:22250–22257. PDF
Borst P, Balzarini J, Ono N, Reid G, de Vries H, Wielinga P, Wijnholds J, Zelcer N. The potential impact of drug transporters on nucleoside-analog-based antiviral chemotherapy. Antiviral Res2004;62:1–7. PDF
Cummings J, Zelcer N, Allen JD, Yao D, Boyd G, Maliepaard M, Friedberg TH, Smyth JF, Jodrell DI. Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins. Biochem Pharmacol 2004;67:31–39. PDF
Reid G*, Wielinga P*, Zelcer N*, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci USA 2003;100:9244–9249. PDF
Zelcer N, Huisman MT, Reid G, Wielinga P, Breedveld P, Kuil A, Knipscheer P, Schellens JHM, Schinkel AH, Borst P. Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem 2003;278:23538–23544. PDF
Reid G, Wielinga P, Zelcer N, de Haas M, Van Deemter L, Wijnholds J, Balzarini J, Borst P. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol 2003;63:1094–1103. PDF
Zelcer N*, Reid G*, Wielinga P, Kuil A, van der Heijden I, Schuetz JD, Borst P. Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J 2003;371:361–367. PDF
Zelcer N, Saeki T, Bot I, Kuil A, Borst P. Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter. Biochem J2003;369:23–30. PDF
Huisman MT, Smit JW, Crommentuyn KML, Zelcer N, Wiltshire HR, Beijnen JH, Schinkel AH. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 2002;16:2295–2301. PDF
Burg D, Wielinga P, Zelcer N, Saeki T, Mulder GJ, Borst P. Inhibition of the multidrug resistance protein 1 (MRP1) by peptidomimetic glutathione-conjugate analogs. Mol Pharmacol2002;62:1160–1166. PDF
Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P. Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem 2001;276:46400–46407. PDF
Borst P, Zelcer N, van Helvoort A. ABC transporters in lipid transport. Biochim Biophys Acta2000;1486:128–144. PDF